Biotechnology in Taiwan

Rakuten Medical

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox® platform, which has been shown to induce rapid and selective cell killing and tumor necrosis. Rakuten Medical is committed to its mission to conquer cancer by delivering its innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit

51 to 200 staff

Anbogen Therapeutics

Anbogen Therapeutics is a clinical stage precision oncology company dedicated in developing first/best-in-class personalized therapeutics and making difference in patients' life. We bridge the gap between discovery candidates and proof-of-concept indications to challenge the unmet needs. Headquartered in Taiwan, we are advancing a pipeline of precision medicines for the treatment of solid tumors. Currently with three assets including ABT-101 and ABT-301 under clinical development.

11 to 50 staff

Atgenomix

Atgenomix is a data and machine learning (ML) company that provides an open standard and unified platform for operationalizing biomedical data, analytics, and ML to deliver on the promise of precision medicine. The Atgenomix cloud-based biomedical informatics platform empowers clinical laboratories to design, develop, and operate GA4GH (Global Alliance for Genomics & Health) standard orchestrated multimodal workflows of data integration, tool engineering, analysis automation, workload acceleration, and regulatory compliance management. At Atgenomix, we envision a technology that will transform healthcare in routine clinical genomics and artificial intelligence. We aim to provide industry accessible computational lab technologies that researchers need to scale data and machine learning in the future. Atgenomix is a Microsoft Azure cloud partner in gold data and cloud platform competencies, and a Google Health trusted partner in genomics research.

11 to 50 staff

Eurofins Discovery

Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, lasting improvements in human health. Join our dynamic team! View open positions:

501 to 1000 staff

A2 Healthcare Taiwan Corporation

As a member of ITOCHU Group, A2 Healthcare Corporation contributes to the research and development of medical and pharmaceutical products through sophisticated offering of clinical research full services with footprints in the US and Asia. In particular, A2 Healthcare specializes in early phase clinical trials, serving hundreds of clients in Taiwan (86%) and worldwide (14%).

51 to 200 staff

Genomics Biosci & Tech Co Ltd

Genomics BioSci & Tech. Co, Ltd. is dedicated to advancing our understanding of genomes, with a focus on their structure, function, evolution, mapping, and editing. We specialize in cutting-edge sequencing technology, bioinformatics, and synthetic biology, enabling us to precisely assemble and analyze gene function and structure. Our services and products empower scientists to tackle real-world challenges, including increasing crop yields through genetically modified plants, developing new drugs, detecting diseases, and providing precision medicine strategies. As Taiwan's premier commercial sequencing company, with over 20 years of expertise in genomic science, Genomics BioSci & Tech. Co, Ltd. has a robust foundation in sequencing services, oligo, and peptide synthesis. We collaborate with leading academic institutions and biotech partners to develop accurate medical genetic testing, offer personalized medical information, and contribute to government research projects aimed at advancing agriculture." Pioneering a new frontier in biotech through sequencing, innovating genetics with cutting-edge cloud solutions." — Dr. Teh-Yuan Chow

51 to 200 staff

Hi-Q Marine Biotech International Ltd

Hi-Q Marine Biotech is founded in 1998, a leading marine biotechnology company in Taiwan. Hi-Q specializes in the research and development of Low Molecular Weight Fucoidan (Oligo Fucoidan), a type of clinically-proven ingredient extracted from natural brown seaweed, developed specifically for nutritional, cosmetic and animal health applications. With the passion of ‘empowering people to lead healthier lives’, Hi-Q are investing in development of cancer nutrition to fulfill the ongoing need to proper and adjunct nutrition to cancer patients as they suffer from cachexia. In addition to the own expert teams, Hi-Q collaborates with leading research institutions for advanced research and solution.#Hi-Q #FucoHiQ #Taiwan #cancer #oncology #nutrition #dietarysupplement #functionalingredients #skincare #cosmeticingredient #kelp #brownseaweed #algae #marine

51 to 200 staff

Energenesis Biomedical

Energenesis Biomedical, founded in 2012, is a biotech company publicly listed on the Taiwan Stock Exchange Corporation (TWSE: 6657) in 2023. With over a decade of commitment, our team has pioneered the ENERGI-Platform, a novel approach using small molecule drugs to boost cellular energy levels. This technology activates self-healing mechanisms within cells, empowering us to explore innovative ways of addressing challenging diseases. Pipeline: ENERGI-F703DFU: gel for Diabetic foot ulcers (Phase recruiting in the US and Taiwan) ENERGI-F701: hair tonic for Alopecia (Phase II, completed) ENERGI-F703EB: cream for Epidermolysis Bullosa (in preparation for Phase II, granted ODD & RPD) ENERGI-F705PD : oral medicine for Parkinson’s disease (in preparation for Phase II)

11 to 50 staff

Fidelity Regulation Therapeutics

Fidelity Regulation Therapeutics Inc, FRT, is a drug development company. Based on the biomedical and basic scientific background, FRT is committed to develop drugs to fulfill unmet medical needs.

1 to 10 staff

Libo Pharma Corp

About Libo Pharma Founded in 2017, Libo Pharma Corp. is dedicated to developing innovative therapies that address significant unmet medical needs. Our lead asset, NM-IL-12, is a first-in-class cytokine-based immunomodulator with multiple mechanisms of action, including immune regulation, hematopoiesis enhancement, radiation damage mitigation, and anti-tumor activity. Our Lead Product: NM-IL-12 NM-IL-12 has received orphan drug designation from both the U.S. FDA and European Medicines Agency (EMA) for the treatment of cutaneous T-cell lymphoma (CTCL) and is advancing into a Phase 3 clinical trial, with strong potential for regulatory approval and commercialization. The product has also completed Phase 2 clinical trials for Hematopoietic Syndrome of Acute Radiation Syndrome(HSARS) and open wound healing, and is currently expanded into new indications including diffuse large B-cell lymphoma (DLBCL) and other solid tumors—highlighting a robust and diversified pipeline. Innovation & Capabilities Libo Pharma maintains a globally competitive intellectual property portfolio, covering key markets such as the United States, Europe, and Japan. We retain full control over the manufacturing processes and biological materials related to NM-IL-12, ensuring a high level of autonomy across product development and production. Backed by a highly experienced scientific and regulatory team, we are well-positioned to drive forward our development programs from clinical validation to commercial launch. Clinical Experience To date, NM-IL-12 has been administered in over 200 human subjects, consistently demonstrating a favorable safety and efficacy profile. Its ability to be used in combination with standard therapies including chemotherapy, radiotherapy, and immune checkpoint inhibitors offers promising opportunities to enhance treatment outcomes across multiple cancer types.

11 to 50 staff

Lifeos Genomics

LifeOS Genomics was founded in 2015 on the vision of enabling accessible testing for genetic diseases. To realize this vision, we built the QLoci™ system, a fully automated “sample-to-result” molecular screening platform that offers proprietary multiplex digital PCR (mdPCR™) technology. The breakthrough of our mdPCR™ platform is the marriage of up to 100-plex assay capability in a digital PCR-on-chip format and 0.01% sensitivity, all delivered in a single microfluidic cartridge. This unique ability to provide high multiplicity assays and absolute quantitation with remarkable consistency is a game changer in fulfilling unmet medical needs, particularly in early detection and dynamic therapeutic solutions.

11 to 50 staff

Pacific Deep Ocean Biotech Ltd

Pacific Deep Ocean Biotech Co, Ltd.(PDOB) was formed to pioneer the potential applications of the rich pure source of minerals and trace elements in Deep Ocean Water. We source deep ocean water from a depth of over 600 meters near Taitung and Hualien on the east coast of Taiwan. This is a beautiful region with rugged steep mountains running down to the coast line. Over the last 15 years, the Taiwanese Government has generously sponsored research and development to improve the technologies to access deep ocean water and to concentrate the minerals and trace elements. Additionally, they have sponsored clinical, agricultural, and fisheries trials to establish the merits of deep ocean water. PDOB's mission is to commercialize the many beneficial applications using the deep ocean water. We will continue to undertake research and focus on the potential and exciting biotech applications. We aim to also expand and create employment opportunities that relate to the ocean and the history of the region. The manufacturing facilities already incorporate green technologies and environmental policies to compliment the beautiful landscape. We are seeking to establish partnerships with other innovative companies best in the industry to collaborate and utilizing our unique technologies and experience.

11 to 50 staff

Aeon Biotherapeutics Corp

We believe the only way to the highest quality of life is to have a healthy body and mind. Knowing that all of our patients have unlimited regenerative potentials, we integrate technologies into medicine to develop safer and more efficient therapies to facilitate natural healing processes and strengthen bodily functions. Biological changes will keep on influencing our daily lives; thus, we have begun a never ending quest to explore new solutions. We are Aeon Biotherapeutics and we are dedicated to creating healthier possibilities.

11 to 50 staff

Ever Supreme Bio Technology Co., Ltd. 6712.Two

Ever Supreme Bio Technology is a clinical-stage biotech company focused on developing next-generation allogeneic cell therapies for solid tumors. Its lead candidate, CAR001, combines gamma delta T cells targeting HLA-G with BiTE-mediated PD-L1 engagement to overcome two major barriers in current solid tumor treatment: tumor heterogeneity and immune evasion. With operations in Taiwan and early clinical trials underway, Ever Supreme also runs a revenue-generating CDMO platform and is expanding its pipeline to include stem cell and exosome-based therapies. Backed by a strong IP portfolio across seven countries and deep clinical expertise, the company is strategically positioned to deliver scalable, off-the-shelf immunotherapies that are safe, effective, and globally accessible.

51 to 200 staff

Strong Biotech Corporation

Combined with professionals in clinical gastroenterology, Strong developed Helicobacter pylori in vitro diagnostic devices and related biotech materials. Strong is Taiwan and the world’s first company specializing in producing both paper and gel type Helicobacter pylori in vitro diagnostic test, providing rapid diagnosis of peptic ulcer caused by the H. pylori as the basis of doctor’s prescription.

11 to 50 staff

Apex Biotechnology Corp 1733

1 to 10 staff

Medigen Biotechnology Corp 3176

Medigen Biotechnology Corp (3176) is a biotechnology company based out of Yuanqu Street, Nangang District, Taipei, Taiwan.

11 to 50 staff

Retain Biotech

Retain Biotech is the first joint venture of National Taiwan University and YongLin Healthcare Foundation, incorporating tripartite resources from industry, academia and research sectors. We integrate the research strength from National Taiwan University, years of extensive clinical experience in the field of stem cell therapy from Tai Chen Cell Therapy Center and vast resources put into the fields of preventive medicine and cancer therapy by YongLin Healthcare Foundation. From the perspective of preventive medicine, Retain Biotech achieves personalized healthcare management with the preservation of stem cells or immune cells at the early stage and high-end healthcare management. By integrating big data analysis, the most appropriate disease management will be provided by our service. When disease occur, we can maximize and optimize the application of medical resources.

11 to 50 staff

Immunwork

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

11 to 50 staff

Atp-Bio Co., Ltd

Health and Beauty We Create for the World Private label and contract manufacturing of health and beauty food, drink, and cosmetics. We efficiently supply good-quality products and services.

51 to 200 staff

Development Center For Biotechnology

The Development Center for Biotechnology (DCB) of Taiwan is a non-profit organization supported by the Department of Industrial Technology, Ministry of Economic Affairs. DCB’s objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and train talented workforces in coordination with government, industry, and academic institutions. In line with Taiwan's current biotech-pharma development policy, which emphasizes value-addition and knowledge-basis, DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. The division of Industrial Promotion provides industrial information, services, facilitates technology transfer, and overall foster international partnerships for commercialization. Many of these functions are performed in conjunction with outpost team members managing other government-sponsored programs, such as the Biotechnology and Pharmaceutical Industries Program Office (BPIPO; commissioned by the Industrial Development Bureau, MOEA), and the Nankang Biotech Incubation Center (NBIC; commissioned by the Small and Medium Enterprise Administration, MOEA). DCB is dedicated to R&D in botanic drug products, pharmaceuticals, biologics, animal pharmacology, and innovative and explorative research. DCB also establishes itself as a licensing technology platform. At present, the therapeutic areas for drug development include cancer, diabetes, as well as infectious, inflammatory and cardiovascular diseases.

201 to 500 staff

Aidmics Biotechnology

Aidmics Biotechnology dedicates itself to providing solutions in microscopic scales. Ever since the launch of its very first product, the iSperm Analyzer, Aidmics has received attentions from across the world, including Reuters, Fast Company, among others.

11 to 50 staff

Tools

To accomplish your research work more efficient, we provide "TOOLS" to fulfill all of your creativity needs."TOOLS" specializes in bringing scientists "total solution" products for all applications of biomedical research from DNA to proteins including molecular biology reagents (immunology, PCR, qPCR and nucleic acid purification kits etc.), customized products and services (miRNA mimics and inhibitors, siRNA synthesis and peptide synthesis). Our enthusiastic and professional team is able to offer the right tools to distributors, OEM resellers and researchers with competitive product pricing. Moreover, providing the right information and useful suggestions to researchers are the core values of "TOOLS".

51 to 200 staff

Magqu Co., Ltd

MagQu focuses on creating new technologies and novel products. To do this, MagQu forms an interdisciplinary R&D team, as well as cooperates with professional institutes or experts in the areas of bio-chemistry, protein, nanomaterials, magnetism, electric engineering, software programming, laboratory medicine, clinic medicine, aquaculture etc. So far, MagQu has created more than six innovative technologies and has made them commercialized. Through the marketing of these novel products, we continuously increases its value, and keeps itself at the leading position in the relevant markets. We have utilized our core technology, so-called ImmunoMagnetic Reduction (IMR), to develop dozens of products, such as in-vitro diagnostic (IVD) assay kits and analyzers for colorectal cancer, Alzheimer’s disease, Down’s syndrome, preterm birth, inflammatory disease, grouper viruses etc. The R&D and manufacture of products have been certified with both ISO including 9001 and 13485, and GMP. We successfully made them on the shelf for life-science markets in China, Japan, Korea, Malaysia, Turkey, USA, UK, and Germany.

11 to 50 staff

Syneurx International Taiwan Corp

Mission The mission of SyneuRx is to use a humanistic approach to bring breakthrough therapeutics to diseases and conditions where there are significant unmet needs. Antiviral Platform - Antiviral for COVID-19 Currently, SyneuRx is conducting two clinical programs of COVID-19 treatments— Pentarlandir® as an oral capsule and Airnecflu® as an inhaled treatment. The company’s COVID-19 efforts began in February 2020 as COVID-19 emerged to be a global pandemic, SyneuRx decided to apply its extensive R&D experience with CNS therapeutics toward R&D for COVID-19 antivirals in an effort to help develop a safe, effective, and accessible treatment that would prevent the progression and transmission of the disease. SyneuRx scientists arrived at the theory that regulatory enzymes such as protease would be a critically-important ‘drug target’ for these types of illnesses, which coincidentally is also a target for several virally-caused diseases such as HIV and hepatitis. Researchers decided to test the company’s proprietary library of compounds against the protease and discovered that the compound that became Pentarlandir proved to be the most safe and efficacious in preclinical tests. Pentarlandir’s ability to block coronavirus replication was confirmed in multiple, rigorous cellular studies and it was also proved to maintain an excellent safety profile, which made Pentarlandir an ideal candidate to go into clinical development. NMDA Platform - Modulation For CNS Disorders A New Perspective on Brain Function Modulation SyneuRx believes that NMDA receptors are the grand regulator of the brain. Therefore, solutions to the current unmet needs in many central nervous system (CNS) disorders need to involve therapies that modulate NMDA receptor functions.

11 to 50 staff

Lucky Flowers Guann-Haw Biotech Corp

Our company is responsible for the lucky flowers anti-mold products business development, marketing, import and export of goods. Lucky flowers anti-mold products including anti-mold stickers and anti-mold packets and so on. Lucky flowers registered trademark and patents worldwide. Lucky flowers run business with Customers all over the world and stand out in the market of anti-mold products. In consideration of the raising trend of green product, lucky flowers correspond with EU biocidal product regulation (BPR). The summit new substance is on the article 95 list since May 2015 and EU REACH pre-registration. lucky flowers product meet SGS ITSTUV…world-famous certification company and test such as: REACH SVHC, DMF free and Rohs. Lucky flowers are a green environmentally friendly high-tech product which can be use wide industries.

11 to 50 staff

Sunway Biotech Co., Ltd

Founded in 2007, SunWay Biotech specializes in advanced microbiological technology and patented fermentation processes. We offer end-to-end solutions, including innovative ingredient development and sales, CDMO/CMO contract manufacturing, proprietary branded products, and brand licensing services. With a strong commitment to scientific validation and product quality, we strive to bring innovative health solutions to global markets, fulfilling our mission:"Make health part of everyday life and unlock infinite possibilities."

51 to 200 staff

Amwise Diagnostic Pte. Ltd

About Amwise Diagnostic We are a leader in precision medicine technology for cancer. Our patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy that has optimal treatment effectiveness and minimal treatment-related adverse events. Unlike current diagnostic techniques, our innovative technology identifies patients who have a definite high risk of recurrence or metastasis, allowing timely administration of necessary treatment. Our existing product assesses an individual breast cancer patient's need for adjuvant treatment with radiation therapy or chemotherapy. In addition, we have expanded our research into the field of colorectal cancer with the hope of helping more cancer patients in the future. Through strategic partnerships and investment links, we have formulated our plans for the Asian region and have started to plan our entrance into Europe and the United States. We envision our technology benefiting a greater number of patients, leading precision medicine in cancer to the next milestone. About RecurIndex® RecurIndex®, which has undergone large-scale clinical validation, integrates genetic mapping of the genes most related to breast cancer recurrence in Asian patients with clinical factors to predict the 5-year risk of local recurrence and distant metastasis. The test results can help doctors and patients have an earlier understanding of cancer characteristics and can serve as an important reference in the determination of appropriate treatment.

11 to 50 staff

Giant Bio Technology Inc

Giant Bio Technology Inc. is a startup company derived from National Taiwan Ocean University, Taiwan. We own a patented technology platform for antibiotic alternatives – Herbmedotcin. Herbmedotcin – a molecular herbal technology that is scientific, provides safer and more effective materials to replace antibiotics, nanometals and chemical preservatives, especially in livestock feed and health care product industries. Use “Herbmedotcin” to produce products, substitute antibiotics, and achieve the goal of natural, non-toxic and effective control of microorganisms. We are open to make business partners both B to B and B to C at national and international level.

1 to 10 staff

Revlis Biotech Company Limited

Our mission is to bring health management to individuals. We aim to position ourselves as a leading healthcare company by leveraging non-invasive technology, artificial intelligence algorithm, and big data processing for personalized service. Founded in 2003, Revlis Biotech Company Ltd. embarked on the development of health and medical products. Cmate, a portable Gen I ECG and the company’s first commercial medical product, has obtained medical grade certification necessary for our launch in 2012. The scalability of our technology and service platform has enabled us to expand our product road-map from fully medical to health & wellness solutions.

51 to 200 staff

Apollo Biotech Co. Ltd

We design and manufacture mass testing solutions for rapid testing of Pathogens, Disease Causing Agents, and Biological Markers. Specifically, we work with manufacturers of COVID-19 Viral Rapid Tests for Antigen, Antibody and most recently Neutralizing Antibodies. Our testing solution is unique in that our iaX-2101 intelligent analyzer eXpress can work with test kits from many manufacturers that have already received Emergency Use Authorization (EUA). More vendors kits are added to our Approved Vendors List every week. Our iaX has passed global Regulatory Approvals and is shipping now. Our Point Of Care (POC) customers are Test Service Providers, Airports, Large Scale Venues, Ticketing system providers, and more. Clinical Labs customers are Vaccine developers, Labs developing test kits etc.

11 to 50 staff

Aquavan Technology Co., Ltd

Aquavan Technology extracts global functional herbal materials and preserve the valuable ingredients which are healthy and nutritional to people via the cutting-edged extraction technology: Supercritical Fluid Extraction. Aquavan also exclusively selected the most precious “No. 4 Hualien Kakorot” cultivated by Taiwan government and Organic farming. Aquavan also established two sub-brands, Tsuie and Axtract in order to provide different aspects of product solutions and approach various type of targeted customers. Tsuie, the brand of nutraceutical products, means the life essences extracted from plants and obtained the nutrition from the daily sunshine, and wish to deliver the most effective and high-quality solutions to the world and make people healthier. Axtract is another brand to promote the extractions from global functional herbal materials, and aims to approach the distributors of extracted materials, and manufactures of herbal nutraceutical products worldwide.

51 to 200 staff

Field Cycling Technology Ltd

We are a team eager to meet the challenges of NMR-related technologies. Our objective is to develop and provide innovative scientific instruments for nuclear magnetic resonance (NMR) research. Nowadays, we specialize in unique instrumentation for High-Resolution Field-Cycling NMR Relaxometry and focus on the continuous development of this technology and the diversity of the Field-Cycling NMR method for academic and industrial purposes. Our high-quality design and manufacture permitted our products to implement for several types of research in the following collaboration partners. We are also actively involved in versatile NMR research.

1 to 10 staff

What's Up Tech

What’s Up is a biotech company that uses artificial intelligence, 5G technology, and big data analysis to effectively find cost-efficient methods and risk-averse solutions to treat medical impairments. Our product allows manufacturers to effortlessly understand the necessary solution so that each step of the supply chain is faster and smoother. The satisfaction and the livelihood of our customers is our highest priority.

1 to 10 staff

Leon Biotech. Co., Ltd

Leon Biotech is established in 2011 as a leading Asia, Taiwan-based Preclinical Contract Research Organization (CRO) providing Integrated Testing & Regulatory Services for medical device companies. We have a state of the art facility with OECD GLP and ISO 17025 accredited, and multiple discipline portfolio service scope; include medical device biocompatibility study; health food toxicology study and consulting. Our team features *Comprehensive one-stop service *Product registration and testing service *Medical device Worldwide Service (European, America, China, Taiwan)*Experts across five industries (pharmaceutical, medical device, cosmetic, food, chemical)

51 to 200 staff

Agrigada Biotech

AgriGADA Biotech was founded in Singapore. We focus on research on herbs’ effects for diseases of civilization, devoted to developing agricultural bio-technology for applications in preventive healthcare. The founders are committed to creating natural health care products that are affordable and accessible to everyone in society, as a humble effort to promote general human health.

1 to 10 staff

Mithra Biotechnology Inc

Mithra Biotechnology Inc. is the first Contract Research Organization (CRO) in Taiwan since 1988. We offer integrated and multi-dimensional CRO services, including bioanalytical services for chemical drugs and biologics, full characterization plans for biologics, bioavailability/bioequivalence (BA/BE) studies, and phase I to IV clinical trials to facilitate pharmaceutical development. Mithra possesses expertise and experience in meeting international standards to serve the fast-growing pharmaceutical industry. We are committed to each project from the very beginning to its completion. It is our goal to exceed clients’ expectations and help achieve your long-term goals.

51 to 200 staff

Level Biotechnology Inc

Level Biotechnology Inc. was founded in 1989. This company was originally set up for marketing and distributing cell culture,immunology, molecular biology products and biomedical precision equipments.We decided to establish CRO for preclinical services for NEC (New entity chemicals), medical device and other related products in Level Biotechnology Inc. is widely recognized as one of the top biotech companies offering excellent products and best preclinical CRO services in Taiwan. With great customer-oriented services, knowledgeable sales representatives, efficient logistics operations,good management experience and well-balanced financial schemes, Level Biotechnology Inc.has already established an excellent reputation and good relationship with customers around the world. We are certificated for consistent service quality by the Our CRO services cover more than 9,900 square yards of laboratory space. The animal facility has been accredited by International since 2007. All areas of the facility are designed and built for comfortable environment for modern contract research studies. All tests conducted are audited by an independent Quality Assurance Unit (QAU) and complied with Good Laboratory Practice(GLP). In addition, more than thirty testing items have been accredited by Taiwan Accreditation Foundation(TAF) in compliance with guide ISO 17025.

51 to 200 staff

Taiwan User-Friendly Sensor & Tech

We are Taiwan User-Friendly Sensor & Tech focusing on food safety issues, especially for food allergy."Test Food Allergen Detection System (TADs)" consists of a test channel, a portable device, and an app system. With the feature of high sensitivity, the device can provide accurate and detailed data about foods in 2 minutes that can help people know more about the allergen contained in foods they are going to eat. We believe that people will get a safer diet in a simple way by using TADs.

1 to 10 staff

T-E Pharma

T-E Pharma Holding owns two subsidiaries: Immunwork, Inc. and T-E Meds, Inc. Immunwork, founded in 2014, is dedicated to the research, development and commercialization of innovative therapeutics based on our proprietary “T-ETM pharmaceuticals” platform. The drug-design platform is employed in the construction of ultra-long-acting peptide therapeutics, antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and other advanced pharmaceutical modalities. To focus development efforts in the ADC/ARC field, Immunwork established T-E Meds, Inc. in 2022 to take over and further develop its ADC and ARC platforms and associated drug candidates. Among our leading clinical assets, TE-8214 and TE-8105, both developed using its ultra-long-acting platform, represent key milestones. TE-8214, targeting neuroendocrine tumors and acromegaly, successfully completed its Phase I trial in June 2025. TE-8105, aimed at treating obesity (including weight management), type 2 diabetes, and fatty liver disease, is expected to complete its Phase I/IIA trial in October 2025. Both candidates have demonstrated good tolerability with no significant side effects. Phase II trials are currently in active preparation. T-E Meds, founded in 2022, focuses exclusively on antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Unlike conventional ADC/ARC platforms that often suffer from low product homogeneity and complex manufacturing processes, T-E Meds employs a proprietary bioconjugation platform that enables streamlined, enzyme-free, site-specific conjugation. This approach yields homogeneous ADCs/ARCs with high drug-to-antibody ratio (DAR), excellent yield, high purity, and flexible payload incorporation. T-E Meds is advancing a robust pipeline of preclinical candidates targeting various cancers, with IND filings for lead candidate planned in 2026 H1.

11 to 50 staff

Mithra Biotechnology Inc

Mithra Biotechnology Inc. is the first Contract Research Organization (CRO) in Taiwan since 1988. We offer integrated and multi-dimensional CRO services, including bioanalytical services for chemical drugs and biologics, full characterization plans for biologics, bioavailability/bioequivalence (BA/BE) studies, and phase I to IV clinical trials to facilitate pharmaceutical development. Mithra possesses expertise and experience in meeting international standards to serve the fast-growing pharmaceutical industry. We are committed to each project from the very beginning to its completion. It is our goal to exceed clients’ expectations and help achieve your long-term goals.

51 to 200 staff

National Health Research Institutes

201 to 500 staff

Cheng Ching Hospital

11 to 50 staff

Mektec Corporation

1 to 10 staff

Play&joy Innovemed Bio-Tech Co., Ltd

The base of natural herbal health materials makes women feel better. The thought design of gender equality is not only the satisfaction of men, but also the pleasure of women.

11 to 50 staff

Eps Bio Technology Corp 4183

麗彤生醫科技股份有限公司

501 to 1000 staff

創生醫電 Plasmonictron

Welcome to page of Tron, we are a start-up company that focus on enabling Plasmonic technology.

1 to 10 staff